Literature DB >> 24556623

Comment on 'Strong reduction of AGO2 expression in melanoma and cellular consequences'.

M Sand1, D Georgas1, S Hessam1, F G Bechara1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24556623      PMCID: PMC4200102          DOI: 10.1038/bjc.2014.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, We would like to congratulate Völler et al (2013) on their recent study showing an unchanged mRNA AGO2 expression in melanoma and a strong reduction of AGO2 expression on protein level. This goes along with the findings in our study on the miRNA processing machinery performed in melanoma, which likewise has previously shown an unchanged mRNA AGO2 expression level in melanoma (Sand ). Interestingly, in contrast to melanoma skin cancer, mRNA AGO2 expression levels in epithelial skin cancer (both cutaneous squamous cell and basal cell carcinoma) were significantly higher (P<0.05) compared with healthy controls (Sand , 2012a, 2012b). Although we do agree with the authors that a deregulation of microRNA (miRNA) was observed in several types of cancer and particularly in skin cancer, with reference to our previous studies we do not agree that changes in the miRNA processing enzymes have not been analysed until today as stated in their abstract (Sand , 2011, 2012d, 2012e, 2013; 2014; Sand and Skrygan, 2014).
  12 in total

Review 1.  MicroRNAs and the skin: tiny players in the body's largest organ.

Authors:  Michael Sand; Thilo Gambichler; Daniel Sand; Marina Skrygan; Peter Altmeyer; Falk G Bechara
Journal:  J Dermatol Sci       Date:  2008-12-05       Impact factor: 4.563

2.  Expression profiling of components of the miRNA maturation machinery.

Authors:  Michael Sand; Marina Skrygan
Journal:  Methods Mol Biol       Date:  2014

Review 3.  The pathway of miRNA maturation.

Authors:  Michael Sand
Journal:  Methods Mol Biol       Date:  2014

4.  Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma.

Authors:  Michael Sand; Marina Skrygan; Dimitrios Georgas; Daniel Sand; Stephan A Hahn; Thilo Gambichler; Peter Altmeyer; Falk G Bechara
Journal:  J Dermatol Sci       Date:  2012-09-13       Impact factor: 4.563

5.  Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer.

Authors:  Michael Sand; Thilo Gambichler; Marina Skrygan; Daniel Sand; Nina Scola; Peter Altmeyer; Falk G Bechara
Journal:  Cancer Invest       Date:  2010-07       Impact factor: 2.176

6.  The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi.

Authors:  Michael Sand; Marina Skrygan; Dimitrios Georgas; Daniel Sand; Thilo Gambichler; Peter Altmeyer; Falk G Bechara
Journal:  Cell Tissue Res       Date:  2012-06-17       Impact factor: 5.249

7.  Expression of microRNAs in basal cell carcinoma.

Authors:  M Sand; M Skrygan; D Sand; D Georgas; S A Hahn; T Gambichler; P Altmeyer; F G Bechara
Journal:  Br J Dermatol       Date:  2012-08-20       Impact factor: 9.302

8.  Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer.

Authors:  Michael Sand; Marina Skrygan; Dimitrios Georgas; Christoph Arenz; Thilo Gambichler; Daniel Sand; Peter Altmeyer; Falk G Bechara
Journal:  Mol Carcinog       Date:  2011-10-24       Impact factor: 4.784

Review 9.  MicroRNA in non-melanoma skin cancer.

Authors:  Michael Sand; Daniel Sand; Peter Altmeyer; Falk G Bechara
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

10.  Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.

Authors:  Michael Sand; Marina Skrygan; Daniel Sand; Dimitrios Georgas; Thilo Gambichler; Stephan A Hahn; Peter Altmeyer; Falk G Bechara
Journal:  Cell Tissue Res       Date:  2012-10-31       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.